Baxter's TricOs orthobiologic:
This article was originally published in Clinica
The FDA has given Baxter Healthcare 510(k) clearance to market its first orthobiologic product in the US. The TricOs T bone void filler is indicated for use in voids in bone that are not intrinsic to the stability of the bony structure, including bone defects from surgery or traumatic injury. Full US market availability of the product should occur in the second half of 2006, said the Deerfield, Illinois firm.